Monoclonal Antibodies Quality & Regulatory Requirements

Key challenges include evolving EMA/FDA expectations, CMC data consistency, comparability, process control, analytical lifecycle management and quality documentation. This training helps participants understand current regulatory priorities and apply them more confidently across mAb development, approval and post-approval lifecycle activities.

The course supports CMC teams by focusing on process characterisation, critical quality attributes, control strategy, qualification and regulatory expectations for BLA and MAA submissions. Participants gain clearer insight into how quality, manufacturing and analytical data should connect across the development pathway.

Comparability is central when process, site, scale, formulation or lifecycle changes may affect product quality. The training covers ICH Q5E, comparability protocols and change management, helping teams better understand how manufacturing changes are assessed within regulatory frameworks.

Relevant areas include analytical product profile, method lifecycle management, reference standards, stability, comparability studies, glycosylation, potency, purity and impurity profiling. The training helps QC, QA and analytical teams see how these topics support consistent product quality and regulatory confidence.

The agenda touches on mAb quality attributes, analytical characterisation, stability, potency, safety and manufacturing complexity. Participants can strengthen their understanding of how impurity profiling and product-related variants fit into broader quality, CMC and regulatory discussions.

Biosimilar developers need to understand analytical comparability, reference product alignment, residual uncertainty and evolving expectations for evidence packages. This training connects biosimilarity, comparability and CMC strategy, helping teams interpret current regulatory trends without relying on outdated assumptions.

Yes. The course includes additional considerations for antibody drug conjugates, bispecific antibodies and other complex antibody formats. It is relevant for teams managing advanced mAb modalities where quality, characterisation, manufacturability and regulatory expectations can be more demanding.

Lifecycle management affects post-approval changes, process validation, continuous process verification, technology transfer and control strategy updates. This training helps QA and regulatory professionals understand how lifecycle decisions influence compliance, dossier maintenance and long-term product quality.

The course is designed for biopharma professionals in Quality, CMC, Regulatory Affairs, Analytical, R&D, Manufacturing and Process Development. It is valuable for both junior and experienced specialists seeking a clearer view of mAb quality expectations and regulatory decision-making.